– USA, MA – Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye, today announced the appointment of Dan Myers to its Board of Directors.
“We are very pleased to welcome Dan to our Board of Directors,” said Board chairman and CEO, Mark Iwicki. “Dan has an extensive background in ophthalmology and his commercial and significant corporate strategy experience will be instrumental as we execute on our vision of delivering new therapies for people living with ocular disease. We look forward to his insights on our commercial products EYSUVIS and INVELTYS, as well as with his guidance more broadly as we pursue our goal of establishing Kala as a leader in the treatment of eye diseases.”
Mr. Myers will join the Compensation and Nominating and Corporate Governance Committees.
Concurrently, the company also announced that Board member Rajeev Shah will be leaving the Board.
About C. Daniel Myers
Mr. Myers is currently the CEO of MediPrint Ophthalmics, Inc. (formerly Leo Lens Pharma), a position he has held since 2020. Before that, he was the co-founder and CEO of Alimera Sciences, where he continues to serve as Non-Executive Chairman of the Board of Directors. Before founding Alimera, Mr. Myers was a founding employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as President from 1997 to 2003 and as VP of Sales and Marketing from 1991 to 1997. He previously served on the Board of Directors of Ocular Therapeutix, Inc. from 2009 to 2012.
“I am excited to support Kala in its efforts to change the treatment paradigm for ocular diseases and am particularly enthusiastic about the opportunity for EYSUVIS to meaningfully improve the care of people living with dry eye disease,” commented Dan Myers. “I look forward to collaborating with the management team and the other members of Kala’s Board, and to offering my perspective on strategic initiatives including the expansion of Kala’s pipeline.”
Mr. Myers holds a B.S. in Industrial Management from the Georgia Institute of Technology.
About Kala Pharmaceuticals:
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY mucus-penetrating particle Drug Delivery Technology to two ocular therapies, EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
For more information: https://www.kalarx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.